GlassScriptPhysician profile
Jillian Steyl
NPI 1619638632
$4,910.23
in general payments reported to CMS, 2019-2025
36 companies · $2,291 in 2025
The $2,291 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $179 · 2023: $2,242 · 2024: $198 · 2025: $2,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,320 · Travel and Lodging: $1,411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,319.96 |
| Travel and Lodging | $1,411.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,742.89 | 2025 | Cygnus Dual, Affinity, Novachor |
| Abbvie INC. | $431.07 | 2023-2025 | |
| Lilly USA, LLC | $295.03 | 2023 | Mounjaro, Emgality, Jardiance |
| Abiomed | $268.74 | 2024-2025 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $235.35 | 2022-2023 | |
| Novo Nordisk INC | $231.63 | 2022-2023 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $205.95 | 2023 | Farxiga, Breztri |
| Glaxosmithkline, LLC. | $182.29 | 2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Intra-Sana Laboratories | $142.46 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.60 | 2022-2023 | Jardiance |
| Exact Sciences Corporation | $133.50 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $132.44 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $87.56 | 2023 | Rexulti |
| Shockwave Medical, INC | $57.68 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abbott Laboratories | $57.33 | 2023 | Freestyle Libre 3 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $51.48 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Idorsia Pharmaceuticals US INC | $49.10 | 2023 | Quviviq |
| Boston Scientific Corporation | $46.82 | 2023 | Watchman Access System |
| Surmodics, INC. | $45.52 | 2025 | Pounce Thrombectomy, Pounce Venous Thrombectomy System, Sublime Microcatheter, 018, 200cm, Straight |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.09 | 2023 | Xifaxan, Trulance |
| Sanofi Pasteur INC. | $33.72 | 2022-2023 | |
| Chiesi USA, INC. | $31.94 | 2024 | Cleviprex, Kengreal |
| Janssen Pharmaceuticals, INC | $31.12 | 2023-2024 | Xarelto |
| Dynavax Technologies Corporation | $30.76 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.65 | 2022 | |
| Biogen, INC. | $23.38 | 2023 | Skyclarys |
| Sanofi-Aventis U.S. LLC | $23.26 | 2023 | |
| Amgen INC. | $21.06 | 2023 | Otezla, Repatha |
| Lexicon Pharmaceuticals, INC. | $18.41 | 2023 | Inpefa |
| Astellas Pharma US INC | $18.35 | 2023 | Veozah |
| Kowa Pharmaceuticals America, INC. | $15.10 | 2023 | Seglentis, Livalo |
| Solventum Corporation | $15.01 | 2025 | V.A.C. Veraflo, Activ.A.C. |
| Merck Sharp & Dohme LLC | $13.62 | 2023 | Vaxneuvance, Gardasil 9 |
| Currax Pharmaceuticals LLC | $13.40 | 2023 | Contrave |
| Dexcom, INC. | $13.28 | 2023 | Dexcom G6 Transmitter |
| Avanir Pharmaceuticals, INC. | $11.64 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Steyl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.